View Older Stories View More Recent Stories

Jun 21, 2024 07:30PM Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Met
Jun 21, 2024 06:59AM Bristol-Myers Squibb (BMY) Receives EMA Validation of Application for Subcutaneous Nivolumab
Jun 21, 2024 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
Jun 20, 2024 06:59AM Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
Jun 18, 2024 04:16PM Bristol-Myers Squibb (BMY) Appoints Michael R. McMullen to its Board
Jun 18, 2024 04:16PM Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors
Jun 18, 2024 06:59AM Bristol Myers Squibb Announces Dividend
Jun 17, 2024 09:45AM Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
Jun 13, 2024 04:47PM Bristol-Myers Squibb (BMY) Announces FDA Granted Accelerated Approval of Augtyro
Jun 13, 2024 04:46PM U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastati
Jun 12, 2024 01:50AM Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb
Jun 5, 2024 09:30AM Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic Pipeline and Expand Depth and Breadth of Commercial Offerings
Jun 4, 2024 08:52AM Bristol-Myers Squibb (BMY) Said Opdivo and Yervoy Combo Significantly Improves Overall Survival in advanced HCC
Jun 4, 2024 08:00AM Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advance
Jun 4, 2024 06:59AM Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Jun 3, 2024 10:13AM Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
Jun 3, 2024 08:00AM Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
Jun 1, 2024 08:00AM KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Canc
May 30, 2024 11:52AM Bristol-Myers Squibb (BMY): FDA Approves Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
May 30, 2024 11:51AM U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
May 29, 2024 07:00AM Bristol-Myers Squibb (BMY) Receives EU Approval for Opdivo in Combination with Cisplatin and Gemcitabine
May 29, 2024 06:59AM Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Me
May 28, 2024 04:06PM Prothena (PRTA) Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019
May 23, 2024 05:05PM Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel
May 23, 2024 06:59AM Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting
May 22, 2024 11:15AM Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
May 22, 2024 06:59AM Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries
May 22, 2024 03:30AM NeoPhore closes oversubscribed Series B extension round with additional funding from Bristol Myers Squibb
May 21, 2024 08:45AM Bristol Myers Squibb, Taye Diggs and Schizophrenia Community Partner to Empower People with Schizophrenia Through Live Your PosSCZible Campaign
May 21, 2024 06:59AM Bristol-Myers Squibb (BMY) Announces Update FDA Action Date for Subcutaneous Nivolumab
May 21, 2024 06:59AM Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
May 16, 2024 10:26AM New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
May 16, 2024 05:22AM Bristol-Myers Squibb (BMY) Announces Breyanzi Approved by the FDA for Relapsed or Refractory Follicular Lymphoma
May 15, 2024 08:57PM Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
May 10, 2024 04:31PM Bristol-Myers Squibb (BMY) Provides Update on Phase 3 CheckMate -73L Trial
May 10, 2024 04:30PM Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
May 8, 2024 07:00AM Immunocore reports first quarter financial results and provides a business update
May 7, 2024 06:59AM Bristol Myers Squibb to Participate in Upcoming Investor Conferences
May 6, 2024 06:59AM Bristol-Myers Squibb (BMY) Announces FDA Acceptance of Application for Subcutaneous Nivolumab
May 6, 2024 06:59AM Bristol-Myers Squibb (BMY) Reports EMA Validated Application for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite
May 6, 2024 06:59AM U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
May 6, 2024 06:59AM European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
Apr 29, 2024 06:02AM Bristol-Myers Squibb (BMY) and Repertoire Enter Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Apr 29, 2024 06:00AM Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
Apr 26, 2024 06:59AM CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Un
Apr 25, 2024 06:59AM Bristol Myers Squibb Reports First Quarter Financial Results for 2024
Apr 25, 2024 05:22AM PureTech Announces Annual Results for Year Ended December 31, 2023
Apr 22, 2024 07:00AM Bristol-Myers Squibb (BMY) and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies
Apr 22, 2024 06:59AM Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients
Apr 8, 2024 11:31AM Bristol-Myers Squibb's (BMY) KRAZATI in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Local
View More Recent Stories View Older Stories